ArticleLiterature Review

Formulation and special investigations of innovative intraoral solid dosage forms

Authors:
To read the full-text of this research, you can request a copy directly from the authors.

Abstract

During our work, we summarized the types of solid dosage forms which were in the focus of attention in the last years because of their innovative pharmaceutical technology solution and simple use. The biopharmaceutics of solid dosage forms for intraoral use and the advantages of the use of these dosages forms were presented in general. However, these dosage forms cannot always be prepared with conventional pharmaceutical processes, therefore the special pharmaceutical solutions which can be applied for their preparation were presented. In addition to testing the European Pharmacopoeia dosage forms, the special tests which can be applied for the characterization of innovative solid dosage forms were highlighted.

No full-text available

Request Full-text Paper PDF

To read the full-text of this research,
you can request a copy directly from the authors.

ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
The active pharmaceutical ingredient can be administered by several different routes. Although the oral route (per os) has been one of the most convenient and widely accepted delivery system for most drugs, it has number of disadvantages like the very low pH of the stomach, the high enzymatic activity, and extensive first-pass metabolism. Difficulty in swallowing (dysphagia) is common among all age groups, especially in "problematical" subpopulations like children and the elderly. Several novel intraoral dosage forms (IODs) have recently become available to modulate the physicochemical and pharmacokinetic characteristics of drugs, while improving patient compliance. The present article summarizes and categorizes their formulation possibilities.
Article
Full-text available
A physically cross-linked palmitoyl glycol chitosan hydrogel has been evaluated as a controlled release system for the delivery of hydrophobic drugs via the buccal route. Samples of palmitoyl glycol chitosan (GCP) with diminishing hydrophobicity (GCP12>GCP11>GCP21) were synthesized, characterized by (1)H nuclear magnetic resonance and hydrogels prepared by freeze-drying an aqueous dispersion of the polymer in the presence of a model hydrophobic drug denbufylline and in some cases the soluble detergent sodium glycodeoxycholate (GDC). GDC was employed as a penetration enhancer. Gels were analysed for hydration, erosion, mucoadhesion and imaged by scanning electron microscopy. The buccal absorption of denbufylline from GCP12, denbufylline, GDC (20:12:1.5) formulations was also investigated in the rabbit model with Carbopol 974NF (CP), denbufylline, GDC (60:36:4) tablets used as controls. Denbufylline reduced the porosity, erosion and hydration of the gels while GDC increased the hydration and erosion. All gels were mucoadhesive but less so than the control CP tablets. Denbufylline was detected 0.5 h after dosing with the GCP12 formulation and delivery was sustained for at least 5 h after dosing. In comparison delivery from the CP tablets was not sustained and was first detected 1 h after dosing.
Article
To explore the acceptance of uncoated drug-free mini-tablets 2 mm in diameter in children aged 0.5-6 years and their ability to swallow the mini-tablets. 60 children aged 0.5-6 years (10 subjects per year of life) were enrolled in our prospective, open random, two-way cross-over exploratory pilot study. The children were administered either an uncoated drug-free mini-tablet 2 mm in diameter with a beverage of their choice or 3 ml of glucose syrup 15% followed by the other formulation. Deglutition was visually assessed for the two different dosage forms using a predefined criteria list. The study hypothesis was that children would accept the liquid formulation better than the solid mini-tablets. Surprisingly, the authors found that the acceptance of the mini-tablets, defined as immediate swallowing or chewing first with subsequent swallowing, was higher or at least equal to that of the syrup. Very young children (6-12 months) were fully capable of swallowing the mini-tablets and may even accept them better than the sweet liquid formulation. Some children aged between 2 and 4 years chewed the tablets before swallowing, but still accepted them quite well. The acceptance rate of the mini-tablets in the different age groups was much higher than expected. Uncoated mini-tablets seem to be a very promising alternative to liquid formulations and could be used at an earlier age in paediatric drug therapy than previously anticipated.
Article
Allergic disease affects an estimated 50% of children worldwide and causes considerable impairment in academic performance and daily activities. Pediatric formulations for allergy treatment are often highly sugared or contain ingredients to improve palatability, appearance, and patient acceptance/adherence. These excipients, however, are associated with dental caries, gastrointestinal intolerance, and dermatologic reactions. To assess the appeal of new sugar-free/dye-free syrup and orodispersible formulations of the second-generation antihistamine desloratadine to parents of children with allergy in four European countries. In an online survey of households with children aged < or =12 years with allergies in France, Italy, the Netherlands, and Spain, respondents were asked to consider one of two desloratadine product concepts: a sugar-free, dye-free oral solution or an orodispersible tablet. Eligible households had to have at least one child aged < or =12 years with symptomatic seasonal, pet, or indoor allergies or hives for > or =1 week/year. Respondents had to be the decision makers regarding their child's allergy medication and to be likely to treat symptoms with prescription medication some of the time. There were 627 eligible households. Most (88%) parents in Spain were likely to ask their physician about and to consider trying sugar-free, dye-free desloratadine syrup, followed by 76% of those in France, 68% in Italy, and 56% in the Netherlands. About three-quarters of parents in France, Spain, and Italy and more than half of those in the Netherlands were likely to ask their physician about and to consider trying the orodispersible formulation. There is no control group for comparisons between the study's online responses and those that would have resulted from another survey methodology. Further, response biases do exist across countries based on cultural norms. Survey respondents were generally receptive to the new sugar-free, dye-free syrup and orodispersible tablet formulations of the second-generation antihistamine desloratadine. At least half of parents surveyed indicated their willingness to try the new products.
Article
The delivery of therapeutic agents to, or via, the oral cavity is limited by the efficient removal mechanisms that exist in this area. Lectins are proteins or glycoproteins that bind to specific sugar residues, and can, therefore, interact with the glycoconjugates present on cell surfaces or salivary mucins. Endogenous lectins could also be used as points of attachment for carbohydrate-containing delivery systems. This review considers the possibility of using lectins as targeting agents within the oral cavity and reports on some of the limited number of studies completed to date. As lectins are multifunctional molecules, the possibility of using them as both targeting and therapeutic agents is considered. Lectin-containing delivery systems are a potential innovation for targeted and prolonged therapy within the oral cavity, but considerations such as toxicity and cost will need to be addressed before their routine use becomes a reality.
Article
A new chewing gum device in the form of a three layers tablet (3TabGum) has been developed. The new drug delivery system is obtained, at room temperature, by direct compression using conventional pharmaceutical equipment. Basically, the resulting chewing gum tablets comprise a gum core combined with two protective antiadherent external layers, which prevent gum adhesion to the punches of the tableting machine. Drug release from a dosage form is the critical step in drug absorption and bioavailability, thus an experimental protocol has been designed to evaluate the efficiency of this kind of therapeutic system by verifying its capability to release the drug dose and by assessing the delivery rate. Simple diffusion into the medium causes the release of only a small percentage of the drug contained in the medicated chewing gum, while the delivery of the major part of the dose occurs during mastication. The results obtained in this study suggest that water soluble drugs are freely and easily released by chewing gums, while for actives characterized by reduced water solubility the release rate depends on the chewing time although all the drugs tested are completely released after a reasonable mastication time.
  • L M C Collins
  • C Dawes
Collins, L.M.C., Dawes, C.: J. Dent Res. 66, 1300-1302 (1987).
  • J W Lee
  • J H Park
  • J R Robinson
Lee, J.W., Park, J.H., Robinson, J.R.: J. Pharm. Sci. 89, 850-866 (2000).
Systemic and oral mucosal drug delivery and delivery systems
  • M J Rathbone
  • G Ponchel
  • F A Ghazali
Rathbone, M.J., Ponchel, G., Ghazali, F.A.: Systemic and oral mucosal drug delivery and delivery systems, in: Rathhbone, M.J. (Ed.): Oral Mucosal Drug Delivery, 74. Marcel Dekker Incs., New York, 1996. pp. 241-284.
  • D Harris
  • J R Robinson
Harris, D., Robinson, J.R.: J. Pharm. Sci. 81, 1-10 (1992).
Oral Histology, Development, Structure and Function
  • C A Squier
  • M W Finkelstei
Squier, C.A., Finkelstei, M.W.-. in: Ten Cate, A.R. (Ed.) Oral Histology, Development, Structure and Function, C.V. Mosby, St. Louis, 1989. pp. 345-385.
  • M E Dowty
  • K E Knuth
  • B K Irons
  • J R Robinson
Dowty, M.E., Knuth, K.E., Irons, B.K., Robinson, J.r.: Pharm. Res. 9, 1113-1122 (1992).
  • P C Fox
Fox, P.C.: Ann. N.Y. Acad. Sci. 842, 132-137 (1998).
  • J D Smart
  • S A Mortazavi
Smart, J.D., Mortazavi, S.A.: J. Pharm. Pharmacol. 47, 1099 (1995).
  • S Law
  • P Wertz
  • D Swartz Endruber
  • C Squier
Law, S., Wertz, P., Swartz endruber, D., Squier, C.: Arch. Oral Biol. 40, 1085-1091 (1995).
Oral Surg. Oral Med. Oral Pathol
  • C Paderni
  • D Compilato
  • L I Giannola
  • G Campisi
Paderni, C., Compilato, D., Giannola, L.I., Campisi, G.: Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 114, 25-34 (2012).
  • M Gott Nek
  • K Hódi
  • G Regdon
Gott nek, M., Hódi, K., ifj. Regdon, G.: Gyógyszerészet 57. 69-75 (2013).
  • K Hermans
  • D Van Den Plas
  • S Kerimova
  • R Carleer
  • P Adriaensens
  • W Weyenberg
  • A Ludwig
Hermans, K., Van den Plas, D., Kerimova, S., Carleer, R., Adriaensens, P., Weyenberg, W., Ludwig, A.: Int. J. Pharm. 472, 10-19 (2014).
  • J G Meher
  • M Tarai
  • N P Yadav
  • A Patnaik
  • P Mishra
  • K S Yadav
J.G. Meher, M. Tarai, N.P. Yadav, A. Patnaik, P. Mishra, K.S. Yadav: Carbohydr. Polym. 96, 172-180 (2013).
Oral Surg. Oral Med. Oral Pathol. Oral Radiol
  • S K Ramineni
  • T D Dziubla
  • L L Cunningham
  • D A Puleo
Ramineni, S.K., Dziubla, T.D., Cunningham Jr., L.L., Puleo, D.A.: Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 118, 665-673 (2014).
  • R R Shiledar
  • A A Tagalpallewar
  • C R Kokare
Shiledar, R.R., Tagalpallewar, A.A., Kokare, C.R.: Carbohydr. Polym. 101, 1234-1242 (2014).
  • A Miro
  • I Angelo
  • A Nappi
  • P La Manna
  • M Biondi
  • L Mayol
  • P Musto
  • R Russo
  • M I La Rotonda
  • F Ungaro
  • F Quaglia
Miro, A., d'Angelo, I., Nappi, A., La Manna, P., Biondi, M., Mayol, L., Musto, P., Russo, R., La Rotonda, M.I., Ungaro, F., Quaglia, F.: Int. J. Pharm. 452, 283-291 (2013).
  • X Q Li
  • Z M Ye
  • J B Wang
  • C R Fan
  • A W Pan
  • C Li
  • R B Zhang
Li, X.Q., Ye, Z.M., Wang, J.B., Fan, C.R., Pan, A.W., Li, C., Zhang, R.B.: Brazilian Journal of Anesthesiology, English Edition, (2016).
  • S Costa Idos
  • R P Abranches
  • M T Garcia
  • M B Pierre
Costa Idos, S., Abranches, R.P., Garcia, M.T., Pierre, M.B.: J. Photochem. Photobiol. B 140, 266-275 (2014).
  • C Cavallari
  • A Fini
  • F Ospitali
Cavallari, C., Fini, A., Ospitali, F.: Eur. J. Pharm. Biopharm. 83, 405-414 (2013).
  • P V Vasantha
  • A Puratchikody
  • S T Mathew
  • A K Balaraman
Vasantha, P.V., Puratchikody, A., Mathew, S.T., Balaraman, A.K.: Saudi Pharm. J. 19, 207-214 (2011).
  • T Pongjanyakul
  • W Khunawatt Anakul
  • C J Strachan
  • K C Gordon
  • S Putt Ipipatkhachorn
  • T Rades
Pongjanyakul, T., Khunawatt anakul, W., Strachan, C.J., Gordon, K.C., Putt ipipatkhachorn, S., Rades, T.: Int. J. Biol. Macromol. 55, 24-31 (2013).
  • E Jones
  • E Ojewole
  • V Pillay
  • P Kumar
  • S Rambharose
  • T Govender
Jones, E., Ojewole, E., Pillay, V., Kumar, P., Rambharose, S., Govender, T.: Int. J. Pharm. 455, 197-212 (2013).
  • M Preis
  • C Woertz
  • K Schneider
  • J Kukawka
  • J Broscheit
  • N Roewer
  • J Breitkreutz
Preis, M., Woertz, C., Schneider, K., Kukawka, J., Broscheit, J., Roewer, N., Breitkreutz, J.: Eur. J. Pharm. Biopharm. 86, 552-561 (2014).
  • M S El-Samaligy
  • S A Yahia
  • E B Basalious
El-Samaligy, M.S., Yahia, S.A., Basalious, E.B.: Int. J. Pharm. 286, 27-39 (2004).
  • M Gott Nek
  • K Süvegh
  • K Pintye-Hódi
  • G Regdon
Gott nek, M., Süvegh, K., Pintye-Hódi, K., Regdon, G.: Radiat. Phys. Chem. 89, 57-63 (2013).
Dynamic Force Measurement in Preformulation of Solid Dosage Forms, Szegedi Tudományegyetem
  • A Kelemen
Kelemen, A.: Dynamic Force Measurement in Preformulation of Solid Dosage Forms, Szegedi Tudományegyetem, Ph.D. Thesis (2012)
  • K Pintye-Hódi
  • G Jr Regdon
  • I Erős
  • K Süvegh
  • T Marek
  • I Kéry
  • R Zelkó
Pintye-Hódi, K., Regdon, G. jr., Erős, I., Süvegh, K., Marek, T., Kéry, I., Zelkó, R.: Int. J. Pharm. 313, 66-71 (2006).
  • J M Gu
  • J R Robinson
  • S H Leung
Gu, J.M., Robinson, J.R., Leung, S.H.: Crit. Rev. Ther. Drug Carr. Syst. 5, 21-67 (1988).
  • J D Smart
Smart, J.D.: Adv. Drug. Deliv. Rev. 57, 1556-1568 (2005).
Formation of bioadhesive bond, lymer Interface and Adhesion
  • S Wu
Wu, S.: Formation of bioadhesive bond, lymer Interface and Adhesion, Marcel Decker Inc, New York, 1982. pp. 359-447.
  • O J Morales
  • J T Mcconville
Morales, O.J., McConville, J.T.: Eur. J. Pharm. Biopharm. 77, 187-199 (2011).
  • E Jabbari
  • S Nozari
Jabbari, E., Nozari, S.: Eur. Polym. J. 36, 2685-2692 (2000).
  • A H Shoajei
  • J Paulspn
  • S Honary
Shoajei, A.H., Paulspn, J., Honary, S.: J. Control. Release 67, 223-232 (2000).
  • T Inoue
  • G Chen
  • A S Hoff Man
Inoue, T. Chen, G. Hoff man, A.S.: J. Bioact. Biocompat. Polym. 13, 50-64 (1998).
  • M Salaman-Miller
  • M Chitt Chang
  • T P Johnson
Salaman-Miller, M., Chitt chang, M.,Johnson, T.P.: Adv. Drug Deliv. Rev. 57, 1666-1691 (2005).
  • I Fiebrig
  • S Harding
  • A Rowe
  • S S Hyman
  • S Davis
Fiebrig, I., Harding, S., Rowe, A., Hyman. S., S., Davis, S.: Carbohydr. Polym. 28, 239-244 (1995).
  • R B Gandhi
  • J R Robinson
Gandhi, R.B., Robinson, J.R.: Adv. Drug. Deliv. Rev. 13, 43-74 (1994).
  • J F Frostner
Frostner, J.F.: Digestion, 17, 234-263 (1978).
  • A Kelemen
  • M Gott Nek
  • G Regdon
  • K Pintye-Hódi
Kelemen, A., Gott nek, M., Regdon Jr., G., Pintye-Hódi, K.: J. Adh. Sci. Technol. 29, 1360-1367 (2015).
Archives de Pédiatrie 11
  • F Rancé
  • B Deslandes
  • P Decosta
Rancé, F., Deslandes, B., Decosta, P.: Archives de Pédiatrie 11, 1127-1130 (2004).
  • Pharmacopoea Hungarica
  • Viii
Pharmacopoea Hungarica editio VIII. Medicina Könyvkiadó, Budapest (2003)
  • F B Abay
  • T Ugurlu
Abay, F.B., Ugurlu, T.: A Short Review J. Pharm. Drug Devel. 3, 303 (2015).
  • I Stoltenberg
  • J Breitkreutz
Stoltenberg, I., Breitkreutz, J.: Eur. J. Pharm. Biopharm. 78, 462-469 (2011).
  • V Klingmann
  • N Spomer
  • C Lerch
  • I Stoltenberg
  • C Fromke
  • H M Bosse
  • J Breitkreutz
  • T Meissner
Klingmann, V., Spomer, N., Lerch, C., Stoltenberg, I., Fromke, C., Bosse, H.M.,Breitkreutz, J., Meissner, T.: J. Pediatr. 163, 1728-1732 (2013).